Compounds > l 689502
Page last updated: 2024-12-11

l 689502

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 689502: HIV-1 protease inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5464037
CHEMBL ID2062158
SCHEMBL ID6366451
MeSH IDM0195515

Synonyms (19)

Synonym
tert-butyl n-[(2s,3s,5r)-3-hydroxy-5-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}-5-({4-[2-(morpholin-4-yl)ethoxy]phenyl}methyl)-1-phenylpentan-2-yl]carbamate
bdbm881
l-685,434 derivative
n-(2(r)-hydroxy-1(s)-indanyl)-5(s)-[(tert-butyloxycarbonyl)amino]-4(s)-hydroxy-6-phenyl-2(r)-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methl]hexanamide
n-(2(r)-hydroxy-1(s)-indanyl)-5(s)-[(tert-butyloxycarbonyl)amino]-4(s)-hydroxy-6-phenyl-2(r)-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]hexanamide
tert-butyl n-[(1s,2s,4r)-1-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxyindan-1-yl]amino]-4-[[4-(2-morpholinoethoxy)phenyl]methyl]-5-oxo-pentyl]carbamate
l-689,502
138483-63-3
l 689502
tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-[[4-(2-morpholin-4-ylethoxy)phenyl]methyl]-6-oxo-1-phenylhexan-2-yl]carbamate
carbamic acid, (5-((2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-4-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-5-oxo-1-(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester, (1s-(1alpha(1r*,2r*,4s*),2alpha))-
carbamic acid, ((1s,2s,4r)-5-(((1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-4-((4-(2-(4-morpholinyl)ethoxy)methyl)-5-oxo-1-(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester
l-689502
CHEMBL2062158
SCHEMBL6366451
DTXSID40160692
CS-7476
HY-U00261
AKOS040741926

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" These changes occurred rapidly, with elevations in serum transaminase observed as early as 6 hr after oral dosing in dogs."( Hepatotoxicity of an HIV protease inhibitor in dogs and rats.
Alberts, DW; Anderson, C; Eydelloth, RS; Grossman, SJ; Patrick, DH; Reinford, N; Smith, PF, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)IC50 (µMol)0.00040.00020.10421.7000AID1795281
Protease Human immunodeficiency virus 1IC50 (µMol)0.00040.00010.22487.3200AID162043; AID162181
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID162181In vitro enzyme inhibitory activity against HIV-1 protease.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104572In vitro anti viral activity against HIV-1(RUTZ) in MT-4 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID224938In vitro anti viral activity against HIV-1(IIIb) in peripheral blood lymphocytes by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID221811In vitro anti viral activity against HIV-1 in human H9 T-lymphoid cell culture by p-24-ELISA assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID162043In vitro inhibition of HIV protease, using a peptide hydrolysis assay1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.
AID78743In vitro anti viral activity against SIV-mac251 in H9 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104573In vitro anti viral activity against HIV-1(WMJ-2) in MT-4 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID78742In vitro anti viral activity against HIV-1(IIIb) in H9 T-lymphoid cell culture by p-24 ELISA assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID78741In vitro anti viral activity against HIV-1(IIIb) in H9 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104435In vitro anti viral activity against HIV-1(MN) in MT-4 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104433In vitro anti viral activity against HIV-1(IIIb) MT-4 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID225332In vitro anti viral activity against HIV-1(SF162) in monocytes/macrophages by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID224939In vitro anti viral activity against HIV-1(IIIb) in peripheral blood lymphocytes by p-24-ELISA assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID226650Ratio of inhibitory activity on HIV-1 protease (IC50) to antiviral activity against HIV-1 in human H9 T-lymphoid cell-ELISA assay(CIC)1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104436In vitro anti viral activity against HIV-1(RF) in MT-4 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID104434In vitro anti viral activity against HIV-1(IIIb) MT-4 T-lymphoid cell culture by p-24-ELISA assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID221810In vitro anti viral activity against HIV-1 in human H9 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID78744In vitro anti viral activity against SIV(mne) in H9 T-lymphoid cell culture by fixed cell immunofluorescence assay1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
AID1795281Protease Inhibition Assay from Article 10.1021/jm00088a003: \\Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.\\1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (90.91)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.96 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetaminophen
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.		1.9810acetamides;
phenols		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		1.9810L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9810azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
saquinavir
Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.		2.3820L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
l 685434
L 685434: structure given in first source; a pseudopeptide with activity against HIV protease		1.9810
pepstatin
pepstatin: inhibits the aspartic protease endothiapepsin		1.9710pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Bile Duct Obstruction
[description not available]		01.9910
Cholestasis
Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).		01.9910